

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2015/035184 A1

(43) International Publication Date
12 March 2015 (12.03.2015)

(51) International Patent Classification:

A61K 31/225 (2006.01) *A61P 31/12* (2006.01)
A61P 25/28 (2006.01) *A61P 29/00* (2006.01)
C07C 235/06 (2006.01) *A61P 11/06* (2006.01)
A61P 31/22 (2006.01) *A61P 3/10* (2006.01)
A61P 31/18 (2006.01) *A61P 17/06* (2006.01)

(21) International Application Number:

PCT/US2014/054319

(22) International Filing Date:

5 September 2014 (05.09.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/874,758 6 September 2013 (06.09.2013) US

(71) Applicant: **XENOPORT, INC.** [US/US]; 3410 Central Expressway, Santa Clara, California 95051 (US).

(72) Inventors: **MAO, Chen**; 100 North Whisman Rd., Apt. 911, Mountain View, California 94043 (US). **SCHEUERMAN, Randall A.**; 963 Sunlite Drive, Santa Clara, California 95050 (US). **KARABORNI, Sami**; 11258 Terra Bella Drive, Cupertino, California 95014 (US).

(74) Agents: **VINNOLA, Milan M.** et al.; Polsinelli PC, 1515 Wynkoop St., Suite 600, Denver, Colorado 80202 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE FORMS OF (N,N-DIETHYLCARBAMOYL)METHYL METHYL (2E)BUT-2-ENE-1,4-DIOATE, METHODS OF SYNTHESIS AND USE

(57) Abstract: Disclosed herein are crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which is a prodrug of methyl hydrogen fumarate. Crystalline form 1, Crystalline form 2, Crystalline form 3, and Crystalline form 4 are disclosed.



WO 2015/035184 A1

**CRYSTALLINE FORMS OF (N,N-DIETHYLCARBAMOYL)METHYL METHYL
(2E)BUT-2-ENE-1,4-DIOATE, METHODS OF SYNTHESIS AND USE**

5

Cross-Reference

This application claims the benefit of U.S. Provisional Application Serial No. 61/874,758, filed September 6, 2013, and entitled "CRYSTALLINE FORMS OF (N,N-DIETHYLCARBAMOYL)METHYL METHYL (2E)BUT-2-ENE-1,4-DIOATE, METHODS OF SYNTHESIS AND USE," the contents of which is incorporated by reference in its entirety.

10

Field

Disclosed herein are novel crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

15

Background

In general, crystalline forms of drugs are utilized in dosage forms rather than amorphous forms of drugs, in part, because of their superior stability. For example, in many situations, an amorphous drug converts to a crystalline drug form upon storage. Because amorphous and crystalline forms of a drug typically have different physical properties, chemical properties, potencies and/or bioavailabilities, such interconversion is undesirable for safety reasons in pharmaceutical administration.

20
25

Polymorphs are crystals of the same molecule which have different physical properties because the crystal lattice contains a different arrangement of molecules. For example, certain polymorphs can include different hydration states that incorporate water into the crystalline structure without chemical alteration of the molecule itself. In that regard, certain compounds can exist in anhydrous and hydrated forms, where the hydrated forms can include, for example, hydrates, dihydrates, trihydrates, and the like, or partial hydrates such as hemihydrates. The different physical properties exhibited by


30

polymorphs can affect important pharmaceutical parameters such as storage, stability, compressibility, density (which is important in formulation and product manufacturing) and dissolution rates (which are important in determining bioavailability). Stability differences may result from changes in chemical reactivity (e.g., differential hydrolysis or oxidation, such that a dosage form discolors more rapidly when the dosage form comprises one polymorph rather than another polymorph), mechanical changes (e.g., tablets crumble on storage as a kinetically favored crystalline form converts to a thermodynamically more stable crystalline form) or both (e.g., tablets of one polymorph are more susceptible to breakdown at high humidity). Solubility differences between polymorphs may, in extreme situations, result in transitions to crystalline forms that lack potency and/or are toxic. In addition, the physical properties of a particular crystalline form may be important in pharmaceutical processing. For example, one particular crystalline form may form solvates more readily or may be more difficult to filter and wash free of impurities than other forms (e.g., particle shape and size distribution might be different between one crystalline form relative to other forms).

Regulatory agencies such as the United States Food and Drug Administration closely regulate the polymorphic content of the active component of a drug in solid dosage forms. In general, regulatory agencies require batch-by-batch monitoring for polymorphic drugs if anything other than the pure, thermodynamically preferred polymorph is marketed. Accordingly, medical and commercial reasons favor synthesizing and marketing the most thermodynamically stable polymorph of a crystalline drug substance in solid drugs, which is substantially free of other, less favored polymorphs.


25

(N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate (**1**) has the following chemical structure:



(1)

Compound (1) is a prodrug of methyl hydrogen fumarate. Once administered, the compound is metabolized *in vivo* into an active metabolite, namely, methyl hydrogen fumarate (MHF) which is also referred to herein as monomethyl fumarate (MMF). The *in vivo* metabolism of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate to MHF/MMF is illustrated below:



Compound (1) is synthesized in Example 1 of Gangakhedkar et al. U.S. Patent No. 8,148,414 and is disclosed as having a melting point between 53 °C and 56 °C. Oral dosage forms comprising compound (1) are disclosed in US Patent Application Serial Nos. 13,973,456 filed August 22, 2013, and 13,973,622 filed August 22, 2013. High drug load formulations of compound (1) are disclosed in US Patent Application Serial No. 13,973,542 filed August 22, 2013. Therapeutic uses and methods of treatment for compound (1) are disclosed in US Patent Application Serial Nos. 13,973,820 filed August 22, 2013, 13/906,155 filed May 30, 2013, 13,973,700 filed August 22, 2013, and 13,973,780 August 22, 2013. Methods of making compound (1) are disclosed in US Patent Application Serial No. 14/298,713 filed June 6, 2014. The contents of each of the above referenced patents and patent applications are hereby incorporated by reference in their entireties.

Co-crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate with different co-formers are disclosed in US Patent Application Serial No. 14/072,138 filed November 5, 2013, the contents of which is hereby incorporated by reference in its entirety.

Summary

The present disclosure describes novel crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate having improved

physicochemical properties that may be used in pharmaceutical processing and in pharmaceutical compositions and therapeutic methods of treatment.

In a first aspect, a crystalline form 1 of (N,N-Diethylcarbamoyl)methyl methyl
5 (2E)but-2-ene-1,4-dioate, pharmaceutical compositions comprising the form 1, and
methods of administering the form 1 to a patient in need thereof for treating a disease,
are provided.

In a second aspect, a crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl
10 (2E)but-2-ene-1,4-dioate, pharmaceutical compositions comprising the form 2, and
methods of administering the form 2 to a patient in need thereof for treating a disease,
are provided.

In a third aspect, a crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl
15 (2E)but-2-ene-1,4-dioate, pharmaceutical compositions comprising the form 3, and
methods of administering the form 3 to a patient in need thereof for treating a disease,
are provided.

In a fourth aspect, a crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl
20 (2E)but-2-ene-1,4-dioate, pharmaceutical compositions comprising the form 4, and
methods of administering the form 4 to a patient in need thereof for treating a disease,
are provided.

Brief Description of the Drawings

25

FIG. 1 is an X-ray powder diffractogram (XRPD) of a crystalline form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 2 is a differential scanning calorimetry (DSC) thermogram of a crystalline
30 form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 3 is thermal gravimetric analysis (TGA) thermogram of a crystalline form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

5 FIG. 4 is an X-ray powder diffractogram (XRPD) of a crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 5 is a differential scanning calorimetry (DSC) thermogram of a crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

10 FIG. 6 is thermal gravimetric analysis (TGA) thermogram of a crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 7 is an X-ray powder diffractogram (XRPD) of a crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

15

FIG. 8 is a differential scanning calorimetry (DSC) thermogram of a crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

20 FIG. 9 is thermal gravimetric analysis (TGA) thermogram of a crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 10 is an X-ray powder diffractogram (XRPD) of a crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

25 FIG. 11 is a differential scanning calorimetry (DSC) thermogram of a crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

FIG. 12 is thermal gravimetric analysis (TGA) thermogram of a crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the present disclosure belongs.

“Bioavailability” refers to the amount of a drug that reaches the systemic circulation of a patient following administration of the drug, or a prodrug thereof, to the patient and may be determined by evaluating, for example, the plasma or blood concentration-versus-time profile for a drug. Parameters useful in characterizing a plasma or blood concentration-versus-time curve include the area under the curve (AUC), the time to maximum concentration (T_{max}), and the maximum drug concentration (C_{max}), where C_{max} is the maximum concentration of a drug in the plasma or blood of a patient following administration of a dose of the drug or prodrug thereof to the patient, and T_{max} is the time to the maximum concentration (C_{max}) of a drug in the plasma or blood of a patient following administration of a dose of the drug or prodrug thereof to the patient.

“Crystalline” means having a regularly repeating arrangement of molecules.

“Crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate” refers to a compound in which crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is not associated with water molecules. Other chemical names for crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate include, without limitation, anhydrous crystalline (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, crystalline polymorphic forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, crystalline forms and anhydrous crystalline polymorphic forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

“Disease” refers to a disease, disorder, condition, symptom, or indication. This term is used interchangeably with the phrase “disease or disorder.”

“Dosage form” refers to a form of a formulation that comprises an amount of active agent or a prodrug of an active agent, for example, the monomethyl fumarate prodrug (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, which can be administered to a patient to achieve a therapeutic effect. An oral dosage form is
5 intended to be administered to a patient via the mouth and swallowed. Examples of oral dosage forms include capsules, tablets, and liquid suspensions. A dose of a drug may include one or more dosage forms administered simultaneously or over a period of time.

10 “Patient” includes mammals, such as for example, humans.

“Pharmaceutical composition” refers to a composition comprising at least one compound provided by the present disclosure and at least one pharmaceutically acceptable vehicle with which the compound is administered to a patient.

15


“Pharmaceutically acceptable” refers to approved or approvable by a regulatory agency of a federal or a state government, listed in the U.S. Pharmacopeia, or listed in other generally recognized pharmacopeia for use in mammals, including humans.

20 “Pharmaceutically acceptable vehicle” refers to a pharmaceutically acceptable diluent, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier, or a combination of any of the foregoing, with which crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-
2-ene-1,4-dioate can be administered to a patient, which does not destroy the
25 pharmacological activity thereof, and which is nontoxic when administered in doses sufficient to provide a therapeutically effective amount of one or both of the compounds.

“Prodrug” refers to a derivative of an active compound (such as a drug) that undergoes a transformation under the conditions of use, such as within the body, to
30 release the active compound or drug. Prodrugs are frequently, but not necessarily, pharmacologically inactive until converted into the active compound or drug. Prodrugs can be obtained by bonding a promoiety (defined herein), typically via a functional

group, to a drug. For example, the monomethyl fumarate prodrug (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is metabolized within a patient's body to form the parent drug monomethyl fumarate.

5 “Promoiety” refers to a group bonded to a drug, typically to a functional group of the drug, *via* one or more bonds that are cleavable under specified conditions of use. The bond(s) between the drug and promoiety may be cleaved by enzymatic or non-enzymatic means. Under the conditions of use, for example following administration to a patient, the bond(s) between the drug and promoiety may be cleaved to release the
10 parent drug. The cleavage of the promoiety may proceed spontaneously, such as *via* a hydrolysis reaction, or may be catalyzed or induced by another agent, such as by an enzyme, by light, by acid, or by a change of or exposure to a physical or environmental parameter, such as a change of temperature, pH, etc. The agent may be endogenous to the conditions of use, such as an enzyme present in the systemic circulation to which
15 the prodrug is administered or the acidic conditions of the stomach, or the agent may be supplied exogenously. For example, the promoiety of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is:



20 “Therapeutically effective amount” refers to the amount of a compound that, when administered to a subject for treating a disease or disorder, or at least one of the clinical symptoms of a disease or disorder, is sufficient to affect such treatment of the disease, disorder, or symptom. The actual amount required for treatment of any particular patient will depend upon a variety of factors including the disorder being
25 treated and its severity; the specific pharmaceutical composition employed; the age, body weight, general health, sex and diet of the patient; the mode of administration; the time of administration; the route of administration; the rate of excretion of a disclosed crystalline form; the duration of the treatment; any drugs used in combination or coincidental with the specific compound employed; the discretion of the prescribing

physician; and other such factors well known in the medical arts. These factors are discussed in Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Tenth Edition, A. Gilman, J. Hardman and L. Limbird, eds., McGraw-Hill Press, 155-173, 2001. A therapeutically effective amount in any given instance can be readily
5 ascertained by those skilled in the art and/or is capable of determination by routine experimentation.

The term "purity", when referring to one of the crystalline forms 1, 2, 3 and/or 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate disclosed herein,
10 means the degree to which the particular crystalline form is undiluted or unmixed with another crystalline form and/or extraneous material(s), and is expressed as a percentage by weight (wt%). The term "purity", when referring to a formulation or dosage form of one of the crystalline forms 1, 2, 3 and/or 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate disclosed herein, which
15 formulation or dosage form comprises the particular crystalline form as the active pharmaceutical agent (as well as one or more other materials such as a pharmaceutically acceptable vehicle), means the degree to which the active pharmaceutical agent in the formulation or dosage form comprises that particular crystalline form and no other crystalline form(s) of (N,N-Diethylcarbamoyl)methyl methyl
20 (2E)but-2-ene-1,4-dioate, and is also expressed as a percentage by weight (wt%). Since the weight percent of a particular crystalline form can vary with measurements taken by different instruments, different calibrations and/or different software packages, those skilled in the art will appreciate that any measured purity level will show some variability. Due to these sources of variability, it is common to recite purity using the
25 word "about" or "at least" when referring to the percent purity of a crystalline form.

"Treating" or "treatment" of any disease or disorder refers to reversing, alleviating, arresting or ameliorating a disease or disorder, or at least one of the clinical symptoms of a disease or disorder, reducing the risk of acquiring at least one of the
30 clinical symptoms of a disease or disorder, inhibiting the progress of a disease or disorder or at least one of the clinical symptoms of the disease or disorder, or reducing the risk of developing at least one of the clinical symptoms of a disease or disorder.

“Treating” or “treatment” also refers to inhibiting the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both, and to inhibiting at least one physical parameter which may or may not be discernible to the patient. In certain embodiments,
5 “treating” or “treatment” refers to protecting against or delaying the onset of at least one or more symptoms of a disease or disorder in a patient.

Reference is now made in detail to certain embodiments of crystalline forms, dosage forms and methods of use. The disclosed embodiments are not intended to be
10 limiting of the claims. To the contrary, the claims are intended to cover all alternatives, modifications, and equivalents.

Detailed Description

15 The present disclosure is directed to crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

Four different crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate are disclosed herein. The first form is form 1. The second form is form
20 2. The third form is form 3. The fourth form is form 4.

Table 1

Crystalline Forms	Melting Point (°C)
Form 1	58
Form 2	50
Form 3	47
Form 4	Unknown

25 As can be seen from the data in Table 1, the form 1, form 2, and form 3 disclosed herein each exhibit a different melting point from each other.

Differential scanning calorimetry, or DSC, is a thermoanalytical technique in which the difference in the amount of heat required to increase the temperature of a sample and reference is measured as a function of temperature. DSC data shows differential heat flow plotted against temperature. As a sample undergoes a thermal event, it is effectively altering the heat flow due to the latent heat associated with the thermal event, which is then reflected as a peak or a shift in baseline. DSC can be used to characterize thermal properties of crystalline forms, such as melting temperature or heat of fusion. Therefore, the melting points of the crystalline form 1, form 2 and form 3 disclosed herein can be characterized by DSC. The crystalline form 4 can be characterized by having a DSC thermogram peak.

Single-crystal X-ray diffraction provides three-dimensional structural information about the positions of atoms and bonds in a crystalline form. It is not always possible or feasible, however, to obtain such a structure from a crystalline form due to, for example, insufficient crystal size or difficulty in preparing crystals of sufficient quality for single-crystal X-ray diffraction. Structural identification information can, however, be obtained from other solid-state techniques such as X-ray powder diffraction and Raman spectroscopy. These techniques are used to generate data on a solid crystalline form. Once that data has been collected on a known crystalline form, that data can be used to identify the presence of that crystalline form in other materials. Thus, these data effectively characterize the crystalline form. For example, an X-ray powder diffraction pattern, or a portion thereof, can serve as a fingerprint which characterizes a crystalline form.

An X-ray powder diffraction plot is an x-y graph with scattering angles 2θ (diffraction) on the x-axis and intensity on the y-axis. The peaks within this plot can be used to characterize a crystalline form. Although the peaks within an entire diffractogram can be used to characterize a crystalline form, a subset of the more characteristic peaks can also be used to accurately characterize a crystalline form. The data is often represented by the position of the peaks on the x-axis rather than the intensity of peaks on the y-axis because peak intensity may vary with sample orientation. There is also variability in the position of peaks on the x-axis. There are

several sources of this variability, one of which comes from sample preparation.

Samples of the same crystalline material prepared under different conditions may yield slightly different diffractograms. Factors such as particle size, moisture content, solvent content, and orientation can affect how a sample diffracts X-rays. Another source of

5 variability comes from instrument parameters. Different X-ray instruments operate using different parameters and these may lead to slightly different diffraction patterns from the same crystalline form. Likewise, different software packages process X-ray data differently and this also leads to variability. These and other sources of variability are known to those of ordinary skill in the art. Due to these sources of variability, it is
10 common to recite X-ray diffraction peaks using the word "about" prior to the peak value in 2θ . The word "about" incorporates this variability which under most sampling conditions, and most data collection and data processing conditions, leads to a variability in peak position of about plus or minus 0.2 scattering angle (2θ). Thus, when a peak is said to be at about 10.5 scattering angle (2θ), under most sampling, data
15 collection, and data processing conditions, that peak will appear anywhere between 10.3 (2θ) and 10.7 (2θ). In characterizing the crystalline forms disclosed herein, the X-ray diffraction peaks were all measured using Cu- K_{α} radiation and all peaks herein cited refer to peaks diffracted from X-rays with that wavelength.

20 High-performance liquid chromatography, or HPLC, is a chromatographic technique used to separate the compounds in a mixture, to identify each compound, and to quantify each compound. HPLC is a technique known in the art to determine the purity of a compound. The purity of forms 1, 2, 3 and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate can be determined using HPLC as is well known to
25 those of ordinary skill in the art.

(N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 1

One crystalline form disclosed herein is form 1 of (N,N-Diethylcarbamoyl)methyl
30 methyl (2E)but-2-ene-1,4-dioate. Differential scanning calorimetry (DSC) analysis of form 1 shows a melting point between about 56 °C and about 60 °C, in certain

embodiments between about 57 °C and about 59 °C, and in certain embodiments at about 58 °C.

The purity of crystalline form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is at least 99 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 1 is at least 99.5 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 1 is at least 99.9 wt% as measured by HPLC.

FIG. 1 is an X-ray powder diffractogram (XRPD) of form 1 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate showing the diffraction pattern measured using Cu-K_α radiation. Table 2 lists the approximate numerical values of the XRPD peak positions of the FIG. 1 diffractogram.

Table 2: XRPD Peaks for (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 1

Peaks (5 Highest Peaks)

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
14.4566	8669.85	0.0836	6.12715	100
21.7146	6282.16	0.1004	4.09281	72.46
12.335	5063.34	0.1004	7.17583	58.4
29.0316	4396.74	0.0836	3.07579	50.71
27.0823	4235.59	0.0836	3.29258	48.85

Peaks (All)

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
6.7857	1705.57	0.0836	13.02663	19.67
10.8529	198.13	0.0836	8.1522	2.29

12.335	5063.34	0.1004	7.17583	58.4
14.4566	8669.85	0.0836	6.12715	100
16.3983	470.36	0.0669	5.40575	5.43
16.9757	538.35	0.1004	5.22316	6.21
17.416	257.63	0.0836	5.0921	2.97
19.7905	2007.61	0.0836	4.48617	23.16
20.2548	1434.71	0.1004	4.38438	16.55
20.6152	1169.49	0.0669	4.30852	13.49
21.0132	3793.73	0.1171	4.22782	43.76
21.7146	6282.16	0.1004	4.09281	72.46
22.7615	3239.73	0.1004	3.90688	37.37
23.0013	484.28	0.1004	3.86669	5.59
23.3254	431.06	0.1171	3.81369	4.97
24.7187	758.12	0.0669	3.60179	8.74
25.8948	817.29	0.1506	3.44081	9.43
27.0823	4235.59	0.0836	3.29258	48.85
28.6898	652.33	0.0836	3.11165	7.52
29.0316	4396.74	0.0836	3.07579	50.71
30.4594	133.22	0.0836	2.93479	1.54
31.2926	291.4	0.1004	2.85852	3.36
31.6493	267.88	0.0836	2.82711	3.09
32.3162	129.32	0.1004	2.77028	1.49
32.7633	277.88	0.1171	2.73349	3.21
33.5857	76.32	0.1004	2.66841	0.88
34.026	399.82	0.0502	2.63488	4.61
35.3367	73.67	0.1338	2.5401	0.85
35.6451	86.4	0.1004	2.51882	1
37.1955	121.88	0.0502	2.41732	1.41
38.2248	40.9	0.2007	2.35456	0.47
39.0281	109.27	0.0836	2.30793	1.26

While the entire diffractogram of FIG. 1 can be used to characterize form 1, form 1 can also be accurately characterized with a subset of that data.

5 In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.2^\circ$, $21.7 \pm 0.2^\circ$, $12.3 \pm 0.2^\circ$, $29.0 \pm 0.2^\circ$, and $27.1 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using $\text{Cu-K}\alpha$ radiation.

10 In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.2^\circ$, $21.7 \pm 0.2^\circ$, $12.3 \pm 0.2^\circ$, $29.0 \pm 0.2^\circ$, $27.1 \pm 0.2^\circ$, $21.0 \pm 0.2^\circ$, $22.8 \pm 0.2^\circ$, $19.8 \pm 0.2^\circ$, $6.8 \pm 0.2^\circ$, and $20.3 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using $\text{Cu-K}\alpha$ radiation.

15 In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.2^\circ$, $21.7 \pm 0.2^\circ$, $12.3 \pm 0.2^\circ$, $29.0 \pm 0.2^\circ$, $27.1 \pm 0.2^\circ$, $21.0 \pm 0.2^\circ$, $22.8 \pm 0.2^\circ$, $19.8 \pm 0.2^\circ$, $6.8 \pm 0.2^\circ$, $20.3 \pm 0.2^\circ$, $20.6 \pm 0.2^\circ$, $25.9 \pm 0.2^\circ$, $24.7 \pm 0.2^\circ$, $28.7 \pm 0.2^\circ$ and $17.0 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using $\text{Cu-K}\alpha$ radiation.

20

In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.1^\circ$, $21.7 \pm 0.1^\circ$, $12.3 \pm 0.1^\circ$, $29.0 \pm 0.1^\circ$, and $27.1 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using $\text{Cu-K}\alpha$ radiation.

25

In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.1^\circ$, $21.7 \pm 0.1^\circ$, $12.3 \pm 0.1^\circ$, $29.0 \pm 0.1^\circ$, $27.1 \pm 0.1^\circ$, $21.0 \pm 0.1^\circ$, $22.8 \pm 0.1^\circ$, $19.8 \pm 0.1^\circ$, $6.8 \pm 0.1^\circ$ and $20.3 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using $\text{Cu-K}\alpha$ radiation.

30

In certain embodiments, form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $14.5 \pm 0.1^\circ$, $21.7 \pm 0.1^\circ$, $12.3 \pm 0.1^\circ$, $29.0 \pm 0.1^\circ$, $27.1 \pm 0.1^\circ$, $21.0 \pm 0.1^\circ$, $22.8 \pm 0.1^\circ$, $19.8 \pm 0.1^\circ$, $6.8 \pm 0.1^\circ$, $20.3 \pm 0.1^\circ$, $20.6 \pm 0.1^\circ$, $25.9 \pm 0.1^\circ$, $24.7 \pm 0.1^\circ$, $28.7 \pm 0.1^\circ$ and $17.0 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K α radiation.

FIG. 2 is a differential scanning calorimetry (DSC) thermogram of form 1 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. The thermogram shows the form 1 has a melting point of about 58 °C.

FIG. 3 is a thermal gravimetric analysis (TGA) thermogram of crystalline form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

(N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 2

One crystalline form disclosed herein is form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. Differential scanning calorimetry (DSC) analysis of this form 2 shows a melting point between about 48 °C and about 52 °C, in certain embodiments between about 49 °C and about 51 °C, and in certain embodiments at about 50 °C.

The purity of crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is at least 99 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 2 is at least 99.5 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 2 is at least 99.9 wt% as measured by HPLC.

FIG. 4 is an X-ray powder diffractogram (XRPD) of form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate showing the diffraction pattern measured using Cu-K α radiation. Table 3 lists the approximate numerical values of the XRPD peak positions of the FIG. 4 diffractogram.

Table 3: XRPD Peaks for (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 2

Peaks (5 Highest Peaks)

5

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
8.4278	11312.51	0.1171	10.49174	100
4.215	9229.54	0.1004	20.96408	81.59
16.8927	2677.65	0.184	5.24863	23.67
18.3421	1829.76	0.1338	4.83704	16.17
19.94	1677.6	0.1338	4.45287	14.83

Peaks (All)

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
4.215	9229.54	0.1004	20.96408	81.59
8.4278	11312.51	0.1171	10.49174	100
10.7747	375.29	0.1004	8.2112	3.32
12.6323	114.89	0.1004	7.00762	1.02
13.023	215.68	0.0669	6.79824	1.91
16.8927	2677.65	0.184	5.24863	23.67
18.3421	1829.76	0.1338	4.83704	16.17
19.94	1677.6	0.1338	4.45287	14.83
20.6716	906.31	0.1004	4.29691	8.01
21.1191	180.15	0.1171	4.20685	1.59
23.5364	1174.76	0.1673	3.77998	10.38
24.1612	475.39	0.0836	3.68363	4.2
25.2828	322.32	0.0836	3.5227	2.85
26.2305	257.88	0.1506	3.39754	2.28
26.8051	1668.51	0.1506	3.326	14.75
27.271	298.92	0.1004	3.27023	2.64

28.9259	81.8	0.1004	3.08679	0.72
29.7727	1023.91	0.102	2.99841	9.05
29.849	862.49	0.0612	2.99835	7.62
30.3802	197.39	0.204	2.93982	1.74
31.3336	54.91	0.1224	2.85251	0.49
32.0775	76.44	0.1224	2.78803	0.68
32.7483	60.19	0.3672	2.73244	0.53
34.1585	232.57	0.1224	2.62279	2.06
38.0932	161.38	0.1224	2.36044	1.43
38.6274	167.17	0.204	2.32901	1.48

While the entire diffractogram of FIG. 4 can be used to characterize form 2, form 2 can also be accurately characterized with a subset of that data.

- 5 In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.2^\circ$, $4.2 \pm 0.2^\circ$, $16.9 \pm 0.2^\circ$, $18.3 \pm 0.2^\circ$, and $20.0 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.
- 10 In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.2^\circ$, $4.2 \pm 0.2^\circ$, $16.9 \pm 0.2^\circ$, $18.3 \pm 0.2^\circ$, $20.0 \pm 0.2^\circ$, $26.8 \pm 0.2^\circ$, $23.5 \pm 0.2^\circ$, $29.8 \pm 0.2^\circ$, $20.7 \pm 0.2^\circ$, and $24.2 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.
- 15 In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.2^\circ$, $4.2 \pm 0.2^\circ$, $16.9 \pm 0.2^\circ$, $18.3 \pm 0.2^\circ$, $20.0 \pm 0.2^\circ$, $26.8 \pm 0.2^\circ$, $23.5 \pm 0.2^\circ$, $29.8 \pm 0.2^\circ$, $20.7 \pm 0.2^\circ$, $24.2 \pm 0.2^\circ$, $10.8 \pm 0.2^\circ$, $25.3 \pm 0.2^\circ$, $27.3 \pm 0.2^\circ$, $26.2 \pm 0.2^\circ$ and $34.2 \pm 0.2^\circ$ in an
- 20 X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.1^\circ$, $4.2 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, $18.3 \pm 0.1^\circ$, and $20.0 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K α radiation.

5

In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.1^\circ$, $4.2 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, $18.3 \pm 0.1^\circ$, $20.0 \pm 0.1^\circ$, $26.8 \pm 0.1^\circ$, $23.5 \pm 0.1^\circ$, $29.8 \pm 0.1^\circ$, $20.7 \pm 0.1^\circ$ and $24.2 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K α radiation.

10

In certain embodiments, form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $8.4 \pm 0.1^\circ$, $4.2 \pm 0.1^\circ$, $16.9 \pm 0.1^\circ$, $18.3 \pm 0.1^\circ$, $20.0 \pm 0.1^\circ$, $26.8 \pm 0.1^\circ$, $23.5 \pm 0.1^\circ$, $29.8 \pm 0.1^\circ$, $20.7 \pm 0.1^\circ$, $24.2 \pm 0.1^\circ$, $10.8 \pm 0.1^\circ$, $25.3 \pm 0.1^\circ$, $27.3 \pm 0.1^\circ$, $26.2 \pm 0.1^\circ$ and $34.2 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K α radiation.

15

FIG. 5 is a differential scanning calorimetry (DSC) thermogram of form 2 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. The thermogram shows form 2 has a melting point of about 50°C .

20

FIG. 6 is a thermal gravimetric analysis (TGA) thermogram of crystalline form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

25 **(N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 3**

One crystalline form disclosed herein is form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. Differential scanning calorimetry (DSC) analysis of this form 3 shows a melting point between about 45°C and about 49°C , in certain embodiments between about 46°C and about 48°C , and in certain embodiments at about 47°C .

30

The purity of crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is at least 99 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 3 is at least 99.5 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 3 is at least 99.9 wt% as measured by HPLC.

FIG. 7 is an X-ray powder diffractogram (XRPD) of form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate showing the diffraction pattern measured using Cu-K α radiation. Table 4 lists the approximate numerical values of the XRPD peak positions of the FIG. 7 diffractogram.

Table 4: XRPD Peaks for (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 3

Pos.[$^{\circ}$ 2Th.]	Height[cts]	FWHM[$^{\circ}$ 2Th.]	d-spacing[\AA]	Rel.Int.[%]
20.6122	2941.88	0.1338	4.30916	100
9.5381	2619.16	0.1004	9.27285	89.03
11.0718	2440.32	0.1004	7.99154	82.95
15.8074	1610.75	0.1004	5.60648	54.75
18.5914	933.36	0.1338	4.77272	31.73

Peaks (All)

Pos.[$^{\circ}$ 2Th.]	Height[cts]	FWHM[$^{\circ}$ 2Th.]	d-spacing[\AA]	Rel.Int.[%]
9.5381	2619.16	0.1004	9.27285	89.03
11.0718	2440.32	0.1004	7.99154	82.95
12.2024	217.18	0.1338	7.25351	7.38
13.2605	219.31	0.1171	6.677	7.45
14.3131	381.18	0.1506	6.18824	12.96
15.8074	1610.75	0.1004	5.60648	54.75

16.3081	78.28	0.2007	5.43546	2.66
18.0005	290	0.1673	4.92804	9.86
18.5914	933.36	0.1338	4.77272	31.73
19.059	829.03	0.0836	4.65666	28.18
19.5156	398.86	0.1171	4.54874	13.56
20.6122	2941.88	0.1338	4.30916	100
20.849	911.14	0.1171	4.26073	30.97
21.5204	505.59	0.1171	4.12931	17.19
22.191	706.92	0.1171	4.00602	24.03
22.8235	454.03	0.1171	3.89642	15.43
23.5381	206.41	0.1506	3.77971	7.02
24.3024	685.9	0.1338	3.66254	23.31
24.8546	140.84	0.1338	3.58241	4.79
26.6025	506.3	0.1506	3.35087	17.21
27.6745	302.27	0.1338	3.22345	10.27
29.1631	876.91	0.1338	3.06222	29.81
30.2144	205.43	0.1171	2.95802	6.98
31.8002	44.76	0.4015	2.81404	1.52
32.9135	54.11	0.2676	2.72136	1.84
33.5305	133.79	0.1338	2.67268	4.55
35.1623	123.35	0.1338	2.5523	4.19
37.5326	48.52	0.3346	2.39638	1.65
39.1007	49.52	0.2007	2.30381	1.68

While the entire diffractogram of FIG. 7 can be used to characterize form 3, form 3 can also be accurately characterized with a subset of that data.

- 5 In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.2^\circ$, $9.5 \pm 0.2^\circ$, $11.1 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, and $18.6 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.2^\circ$, $9.5 \pm 0.2^\circ$, $11.1 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, $18.6 \pm 0.2^\circ$, $20.8 \pm 0.2^\circ$, $29.2 \pm 0.2^\circ$, $19.1 \pm 0.2^\circ$, $22.2 \pm 0.2^\circ$, and $24.3 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using
5 Cu- K_α radiation.

In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.2^\circ$, $9.5 \pm 0.2^\circ$, $11.1 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, $18.6 \pm 0.2^\circ$, $20.8 \pm 0.2^\circ$, $29.2 \pm 0.2^\circ$, $19.1 \pm 0.2^\circ$, $22.2 \pm 0.2^\circ$, $24.3 \pm 0.2^\circ$, $26.6 \pm 0.2^\circ$, $21.5 \pm 0.2^\circ$, $22.8 \pm 0.2^\circ$, $19.5 \pm 0.2^\circ$ and $14.3 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
10

In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.1^\circ$, $9.5 \pm 0.1^\circ$, $11.1 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, and $18.6 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
15

In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.1^\circ$, $9.5 \pm 0.1^\circ$, $11.1 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, $18.6 \pm 0.1^\circ$, $20.8 \pm 0.1^\circ$, $29.2 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $22.2 \pm 0.1^\circ$, and $24.3 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
20

In certain embodiments, form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.1^\circ$, $9.5 \pm 0.1^\circ$, $11.1 \pm 0.1^\circ$, $15.8 \pm 0.1^\circ$, $18.6 \pm 0.1^\circ$, $20.8 \pm 0.1^\circ$, $29.2 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $22.2 \pm 0.1^\circ$, $24.3 \pm 0.1^\circ$, $26.6 \pm 0.1^\circ$, $21.5 \pm 0.1^\circ$, $22.8 \pm 0.1^\circ$, $19.5 \pm 0.1^\circ$ and $14.3 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
25

30 FIG. 8 is a differential scanning calorimetry (DSC) thermogram of form 3 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. The thermogram shows the form 3 has a melting point of about 47°C .

FIG 9 is a thermal gravimetric analysis (TGA) thermogram of crystalline form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

5 **(N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 4**

One crystalline form disclosed herein is form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. Differential scanning calorimetry (DSC) analysis of this form 4 shows a polymorphic transformation between about 36 °C and about 40 °C, 10 in certain embodiments between about 37 °C and about 39 °C, and in certain embodiments at about 38 °C.

The purity of crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is at least 99 wt% as measured by HPLC. In certain embodiments the 15 purity of crystalline form 4 is at least 99.5 wt% as measured by HPLC. In certain embodiments the purity of crystalline form 4 is at least 99.9 wt% as measured by HPLC.

FIG. 10 is an X-ray powder diffractogram (XRPD) of form 4 of the (N,N- 20 Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate showing the diffraction pattern measured using Cu-K_α radiation. Table 5 lists the approximate numerical values of the XRPD peak positions of the FIG.10 diffractogram.

25 **Table 5: XRPD Peaks for (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate: Form 4**

Peaks (5 Highest Peaks)

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
20.4421	5428.16	0.1338	4.34461	100
8.1616	5069.85	0.0669	10.8333	93.4
33.2225	4743.54	0.0502	2.69675	87.39

26.2929	4071.97	0.0669	3.38962	75.02
20.8019	3710.75	0.0836	4.27029	68.36

Peaks (All)

Pos.[°2Th.]	Height[cts]	FWHM[°2Th.]	d-spacing[Å]	Rel.Int.[%]
8.1616	5069.85	0.0669	10.8333	93.4
8.2731	3453.55	0.0502	10.68762	63.62
12.3278	178.49	0.1338	7.17997	3.29
13.1556	2023.81	0.1673	6.73003	37.28
13.6427	964.42	0.0836	6.49081	17.77
15.8255	262.36	0.1506	5.6001	4.83
16.4155	1677.54	0.0502	5.40014	30.9
17.1332	312.18	0.1673	5.17549	5.75
17.6134	182.86	0.1338	5.03547	3.37
18.1058	119.69	0.1004	4.89963	2.21
19.4519	904.34	0.184	4.56349	16.66
20.4421	5428.16	0.1338	4.34461	100
20.8019	3710.75	0.0836	4.27029	68.36
21.8182	1151.17	0.1338	4.07361	21.21
22.1297	223.05	0.1338	4.01696	4.11
22.6845	376.22	0.1506	3.91997	6.93
24.7372	700.3	0.1004	3.59914	12.9
26.2091	3212.01	0.0816	3.39745	59.17
26.2929	4071.97	0.0669	3.38962	75.02
26.9684	604.96	0.184	3.30623	11.14
28.6594	687.82	0.1506	3.11488	12.67
29.2511	132.28	0.1338	3.05321	2.44
31.4215	403.53	0.2007	2.84708	7.43
32.0747	298.8	0.1673	2.79058	5.5
33.2225	4743.54	0.0502	2.69675	87.39
35.4358	60.12	0.2007	2.53322	1.11

36.6746	177.18	0.1673	2.45045	3.26
39.5373	106.51	0.1673	2.27938	1.96

While the entire diffractogram of FIG. 10 can be used to characterize form 4, form 4 can also be accurately characterized with a subset of that data.

5 In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.2^\circ$, $8.2 \pm 0.2^\circ$, $33.2 \pm 0.2^\circ$, $26.3 \pm 0.2^\circ$, and $20.8 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.

10 In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.2^\circ$, $8.2 \pm 0.2^\circ$, $33.2 \pm 0.2^\circ$, $26.3 \pm 0.2^\circ$, $20.8 \pm 0.2^\circ$, $8.3 \pm 0.2^\circ$, $26.2 \pm 0.2^\circ$, $13.2 \pm 0.2^\circ$, $16.4 \pm 0.2^\circ$, and $21.8 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.

15 In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.2^\circ$, $8.2 \pm 0.2^\circ$, $33.2 \pm 0.2^\circ$, $26.3 \pm 0.2^\circ$, $20.8 \pm 0.2^\circ$, $8.3 \pm 0.2^\circ$, $26.2 \pm 0.2^\circ$, $13.2 \pm 0.2^\circ$, $16.4 \pm 0.2^\circ$, $21.8 \pm 0.2^\circ$, $13.6 \pm 0.2^\circ$, $19.4 \pm 0.2^\circ$, $24.7 \pm 0.2^\circ$, $28.7 \pm 0.2^\circ$, and $27.0 \pm 0.2^\circ$ in an
20 X-ray powder diffraction pattern measured using Cu- K_α radiation.

 In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.1^\circ$, $8.2 \pm 0.1^\circ$, $33.2 \pm 0.1^\circ$, $26.3 \pm 0.1^\circ$, and $20.8 \pm 0.1^\circ$ in an X-ray powder diffraction pattern
25 measured using Cu- K_α radiation.

 In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.1^\circ$, $8.2 \pm 0.1^\circ$, $33.2 \pm 0.1^\circ$, $26.3 \pm 0.1^\circ$, $20.8 \pm 0.1^\circ$, $8.3 \pm 0.1^\circ$, $26.2 \pm 0.1^\circ$, $13.2 \pm 0.1^\circ$, $16.4 \pm$

0.1°, and $21.8 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K_α radiation.

In certain embodiments, form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-
5 2-ene-1,4-dioate exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.1^\circ$, $8.2 \pm 0.1^\circ$, $33.2 \pm 0.1^\circ$, $26.3 \pm 0.1^\circ$, $20.8 \pm 0.1^\circ$, $8.3 \pm 0.1^\circ$, $26.2 \pm 0.1^\circ$, $13.2 \pm 0.1^\circ$, $16.4 \pm 0.1^\circ$, $21.8 \pm 0.1^\circ$, $13.6 \pm 0.1^\circ$, $19.4 \pm 0.1^\circ$, $24.7 \pm 0.1^\circ$, $28.7 \pm 0.1^\circ$, and $27.0 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K_α radiation.

10 FIG. 11 is a differential scanning calorimetry (DSC) thermogram of form 4 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate. The thermogram shows the form 4 has a melting point of about 38°C .

15 FIG. 12 is a thermal gravimetric analysis (TGA) thermogram of crystalline form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate.

Pharmaceutical Compositions

The present disclosure relates to pharmaceutical compositions comprising a
20 therapeutically effective amount of a crystalline form of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate together with a suitable amount of one or more pharmaceutically acceptable vehicle so as to provide a composition for proper administration to a patient. The crystalline form 1, form 2, form 3, and form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-
25 dioate disclosed herein have the same pharmaceutical activity as the respective active pharmaceutical ingredient (API). Suitable pharmaceutical vehicles are described in the art.

Pharmaceutical compositions for the treatment of any one or more diseases and
30 disorders comprise a therapeutically effective amount of a crystalline form disclosed herein as appropriate for treatment of a patient with the particular disease(s) or disorder(s).

A pharmaceutical composition may be any pharmaceutical form which maintains the crystalline form of a disclosed crystalline form. In certain embodiments, the pharmaceutical composition may be selected from a solid form, a liquid suspension, an injectable composition, a topical form, and a transdermal form.

Depending on the type of pharmaceutical composition, the pharmaceutically acceptable vehicle may be chosen from any one or a combination of vehicles known in the art. The choice of the pharmaceutically acceptable vehicle depends upon the pharmaceutical form and the desired method of administration to be used. For a pharmaceutical composition comprising a crystalline form disclosed herein, a vehicle should be chosen that maintains the crystalline form. In other words, the vehicle should not substantially alter the crystalline form of the crystalline form. For example, a liquid vehicle which would dissolve the crystalline form should not be used. Nor should the vehicle be otherwise incompatible with a crystalline form, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.

In some embodiments, the pharmaceutical compositions are formulated in unit dosage forms for ease of administration and uniformity of dosage. A "unit dosage form" refers to a physically discrete unit of therapeutic agent appropriate for the patient to be treated. It will be understood, however, that the total daily dosage of a crystalline form and its pharmaceutical compositions will typically be decided by the attending physician within the scope of sound medical judgment.

Because the crystalline forms disclosed herein are more easily maintained during their preparation, solid dosage forms may be employed in numerous embodiments for the pharmaceutical compositions. In some embodiments, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable vehicle such as sodium citrate or dicalcium phosphate. The solid dosage form may also include one or more of: a) fillers or

extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginate, certain silicates, and sodium carbonate; e) dissolution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate. The solid dosage forms may also comprise buffering agents. They may optionally comprise opacifying agents and can also be of a composition such that they release the active ingredient(s) only in a certain part of the intestinal tract, optionally, in a delayed manner. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various vehicles used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Solid dosage forms of pharmaceutical compositions can also be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.

20 A crystalline form disclosed herein can be in a solid micro-encapsulated form with one or more vehicles as discussed above. Microencapsulated forms of a crystalline form may also be used in soft and hard-filled gelatin capsules with vehicles such as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

25 Also disclosed herein are methods for the treatment of the disorders disclosed herein. The crystalline forms, and pharmaceutical compositions comprising them, may be administered using any amount, any form of pharmaceutical composition and any route of administration effective for the treatment. After formulation with an appropriate pharmaceutically acceptable vehicle in a desired dosage, as known by those of skill in the art, the pharmaceutical compositions can be administered to humans and other animals orally, rectally, parenterally, intravenously, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or

nasal spray, or the like, depending on the location and severity of the condition being treated. In certain embodiments, the crystalline forms may be administered at dosage levels of about 0.001 mg/kg to about 50 mg/kg, from about 0.01 mg/kg to about 25 mg/kg, or from about 0.1 mg/kg to about 10 mg/kg of subject body weight per day, one
5 or more times a day, to obtain the desired therapeutic effect. It will also be appreciated that dosages smaller than 0.001 mg/kg or greater than 50 mg/kg (for example 50-100 mg/kg) can be administered to a subject.

Therapeutic Uses

10 The crystalline forms 1, 2, 3, and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate disclosed herein may be used to treat diseases, disorders, conditions, and/or symptoms of any disease or disorder for which MHF is known to provide, or is later found to provide, therapeutic benefit. MHF is known to be effective
15 in treating psoriasis, multiple sclerosis, an inflammatory bowel disease, asthma, chronic obstructive pulmonary disease, and arthritis, among others. Hence, the crystalline forms 1, 2, 3, and 4 disclosed herein may be used to treat any one or more of the foregoing diseases and disorders. The underlying etiology of any of the foregoing diseases being treated may have a multiplicity of origins. Further, in certain
20 embodiments, a therapeutically effective amount of one or more of the crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate may be administered to a patient, such as a human, as a preventative measure against various diseases or disorders.

25 The crystalline forms 1, 2, 3, and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate disclosed herein can be administered to a patient to treat or prevent any one or more of the diseases and conditions selected from: acute dermatitis, acute disseminated encephalomyelitis, Addison's disease, adrenal leukodystrophy, AGE-induced genome damage, Alexanders Disease, alopecia areata (totalis and
30 universalis), Alper's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, ankylosing spondylitis, antiphospholipid antibody syndrome, arthritis, asthma, autoimmune carditis, autoimmune hemolytic anemia, autoimmune hepatitis,

autoimmune inner ear disease, balo concentric sclerosis, Behcet's disease, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, celiac disease, central nervous system vasculitis, Chagas disease, Charcott-Marie-Tooth Disease, childhood ataxia with central nervous system

5 hypomyelination, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease, cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, dermatomyositis, diabetes mellitus type I, diabetic retinopathy, eczema, endometriosis, globoid cell leukodystrophy (Krabbe Disease), Goodpasture's syndrome, graft versus host disease, granulomas

10 including annulaire, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hepatitis C viral infection, herpes simplex viral infection, hidradenitis suppurativa, human immunodeficiency viral infection, Huntington's disease, idiopathic thrombocytopenic purpura, IgA neuropathy, inflammatory bowel disease, interstitial cystitis, irritable bowel disorder, ischemia, Kawasaki disease, lichen planus, lupus,

15 lupus erythematosus, macular degeneration, mitochondrial encephalomyopathy, mixed connective tissue disease, monomelic amyotrophy, morphea, multiple sclerosis, myasthenia gravis, myocardial infarction, narcolepsy, neurodegeneration with brain iron accumulation, neuromyelitis optica, neuromyotonia, neurosarcoidosis, NF- κ B mediated diseases, optic neuritis, pareneoplastic syndromes, Parkinson's disease, Pelizaeus-

20 Merzbacher disease, pemphigus, pernicious anaemia, polymyositis, primary biliary cirrhosis, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, reperfusion injury, retinopathia pigmentosa, rheumatica, sarcoidosis, Schilders Disease, schizophrena, scleroderma, Sjogren's syndrome, stiff person syndrome, subacute necrotizing myelopathy, susac syndrome,

25 temporal arteritis, transplantation rejection, transverse myelitis, a tumor, ulcerative colitis, vasculitis, vitiligo, Wegener's granulomatosis and Zellweger's syndrome.

Efficacy of the crystalline forms 1, 2, 3 and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate for treating any of the diseases and conditions listed

30 can be determined using animal models and in clinical trials.

Psoriasis

Psoriasis is characterized by hyperkeratosis and thickening of the epidermis as well as by increased vascularity and infiltration of inflammatory cells in the dermis.

5 Psoriasis vulgaris manifests as silvery, scaly, erythematous plaques on typically the scalp, elbows, knees, and buttocks. Guttate psoriasis occurs as tear-drop size lesions.

Fumaric acid esters are recognized for the treatment of psoriasis and dimethyl fumarate is approved for the systemic treatment of psoriasis in Germany (Mrowietz and
10 Asadullah, *Trends Mol Med* (2005), 11(1): 43-48; and Mrowietz *et al.*, *Br J Dermatology* (1999), 141: 424-429).

Efficacy of the crystalline forms 1, 2, 3 and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate for treating psoriasis can be determined using animal
15 models and in clinical trials.

Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central
20 nervous system caused by an autoimmune attack against the isolating axonal myelin sheets of the central nervous system. Demyelination leads to the breakdown of conduction and to severe disease with destruction of local axons and irreversible neuronal cell death. The symptoms of MS are highly varied, with each individual patient exhibiting a particular pattern of motor, sensible, and sensory disturbances. MS
25 is typified pathologically by multiple inflammatory foci, plaques of demyelination, gliosis, and axonal pathology within the brain and spinal cord, all of which contribute to the clinical manifestations of neurological disability (see *e.g.*, Wingerchuk, *Lab Invest* (2001), 81: 263-281; and Virley, *NeuroRx* (2005), 2(4): 638-649). Although the causal events that precipitate MS are not fully understood, evidence implicates an autoimmune
30 etiology together with environmental factors, as well as specific genetic predispositions. Functional impairment, disability, and handicap are expressed as paralysis, sensory and octintive disturbances, spasticity, tremor, a lack of coordination, and visual

impairment, any one of which negatively impacts the quality of life of the individual. The clinical course of MS can vary from individual to individual, but invariably the disease can be categorized in three forms: relapsing-remitting, secondary progressive, and primary progressive.

5

Studies support the efficacy of fumaric acid esters for treating MS and fumaric acid esters are presently undergoing phase II clinical testing for such treatment (Schimrigk *et al.*, *Eur J Neurology* (2006), 13: 604-610; and Wakkee and Thio, *Current Opinion Investigational Drugs* (2007), 8(11): 955-962).

10

Assessment of MS treatment efficacy in clinical trials can be accomplished using tools such as the Expanded Disability Status Scale and the MS Functional, as well as magnetic resonance imaging, lesion load, biomarkers, and self-reported quality of life. Animal models of MS shown to be useful to identify and validate potential therapeutics include experimental autoimmune/allergic encephalomyelitis (EAE) rodent models that simulate the clinical and pathological manifestations of MS and nonhuman primate EAE models.

15

The efficacy of the crystalline forms 1, 2, 3, and 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate for treating MS can be determined using animal models and in clinical trials.

20

Examples

25 **Example 1: Synthesis, Purification and Analysis of Crystalline Form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate**

Crystalline form 1 is the thermodynamically stable form at ambient temperature. Because of that, it can be produced by suspending an excess amount of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate solid in an organic solvent for an extended period of time. For example, the pure form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate can be produced by

30

suspending 300 mg (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate solid in 1 mL *tert*-butyl ether (MTBE) at room temperature for 24 hours, followed by vacuum filtration and drying.

5 Differential Scanning Calorimetry (DSC) Analysis

DSC analysis was conducted using a TA Instruments Q2000 DSC equipped with a refrigerated cooling system. For all DSC analyses, 2-5 mg of sample was loaded into T_{zero} aluminum pans with crimped lids. A pinhole was made at the center of the lid to
10 avoid any pressure buildup during heating. Samples were equilibrated at 10 °C and ramped at a heating rate of 10 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data were analyzed with Universal Analysis 2000 software (version 4.5A).

15 The DSC thermogram (FIG. 2) shows that form 1 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate first melts at about 58 °C.

Thermogravimetric Analysis (TGA)

20 Thermal gravimetric analysis was conducted using a TA Instruments Q5000 thermogravimetric analyzer. For all TGA analyses, 5-10 mg of sample was loaded onto a platinum pan and heated at a rate of 10 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data was analyzed with Universal Analysis 2000 software (version 4.5A).

25

The TGA thermogram (FIG 3) shows that form 1 of N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate does not undergo any weight loss prior to melting, which indicates that the form 1 is an anhydrous crystalline solid.

30 X-ray Powder Diffraction (XRPD) Analysis

Powder X-ray diffraction analysis was performed using a PANalytical X'Pert Pro

X-ray diffractometer. The X-ray source was Cu K_{α} radiation ($\lambda = 1.54051 \text{ \AA}$) with output voltage of 45 kV and current of 40 mA. The instrument adopts a para-focusing Bragg-Brentano geometry with incident divergence and scattering slits set at $1/16^{\circ}$ and $1/8^{\circ}$ respectively. Large Soller slits (0.04 rad) were used for both incident and diffracted
5 beam to remove axial divergence. A small amount of powder (9-12 mg) was gently pressed onto the single crystal silicon sample holder to form a smooth surface, and samples were subjected to spinning at a rate of two revolutions per second, throughout the acquisition process. The samples were scanned from 2° to 40° in 2θ with a step size of 0.017° and a scan speed of $0.067^{\circ}/\text{sec}$. The data acquisition was controlled and
10 analyzed by X'Pert Data Collector (version 2.2d) and X'Pert Data Viewer (version 1.2c), respectively.

The X-ray diffraction pattern for form 1 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is shown in FIG. 1. Unless otherwise specified, the
15 experimental data for X-ray powder diffraction were collected at room temperature.

HPLC Analysis

HPLC analysis is performed using an Agilent HPLC, UV detector monitoring at
20 210 nm wavelength, and an Inertsil ODS-4 C-18 chromatography column ($4.6 \times 150 \text{ mm}$, $3\mu\text{m}$ particle size) at 35°C , using an injection volume of a $10 \mu\text{L}$ sample with an approximate concentration of 0.1 mg/mL . The eluent consists of a 30 minute gradient between two separate mobile phases; mobile phase A consisting of water with 0.05% phosphoric acid and mobile phase B consisting of 90% acetonitrile/ 10% water/ 0.05%
25 phosphoric acid at a flow rate of 1 ml/min .

Gradient

Time (min)	%Mobile Phase A	%Mobile Phase B
0	98	2
6	65	35
15	55	45
25	10	90
25.1	98	2
30	98	2

Example 2: Synthesis, Purification and Analysis of Crystalline Form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate

5

Approximately 50 mg of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate was dissolved completely in 1 mL isopropanol/water (1/1 v/v), followed by evaporation of solvent in a fume hood. The obtained crystals after solvent evaporation were shown to be pure form 2.

10

Differential Scanning Calorimetry (DSC) Analysis

DSC analysis was conducted using a TA Instruments Q2000 DSC equipped with a refrigerated cooling system. For all DSC analyses, 2-5 mg of sample was loaded into T_{zero} aluminum pans with crimped lids. A pinhole was made at the center of the lid to avoid any pressure buildup during heating. Samples were equilibrated at 10 °C and ramped to at a heating rate of 2 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data were analyzed with Universal Analysis 2000 software (version 4.5A).

20

The DSC thermogram (FIG. 5) shows that form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate first melts at about 50 °C, followed by recrystallization and melting. The second melting completes at

approximately 60 °C.

Thermogravimetric Analysis (TGA)

5 Thermal gravimetric analysis was conducted using a TA Instruments Q5000 thermogravimetric analyzer. For all TGA analyses, 5-10 mg of sample was loaded onto a platinum pan and heated at a rate of 2 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data was analyzed with Universal Analysis 2000 software (version 4.5A).

10

The TGA thermogram (FIG 6) shows that form 2 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate does not undergo any weight loss prior to melting, which indicates that the form 2 is an anhydrous crystalline solid.

15 X-ray Powder Diffraction (XRPD) Analysis

Powder X-ray diffraction analysis was performed using a PANalytical X'Pert Pro X-ray diffractometer. The X-ray source was Cu K_{α} radiation ($\lambda = 1.54051 \text{ \AA}$) with output voltage of 45 kV and current of 40 mA. The instrument adopts a para-focusing Bragg-Brentano geometry with incident divergence and scattering slits set at $1/16^{\circ}$ and $1/8^{\circ}$ respectively. Large Soller slits (0.04 rad) were used for both incident and diffracted beam to remove axial divergence. A small amount of powder (9-12 mg) was gently pressed onto the single crystal silicon sample holder to form a smooth surface, and samples were subjected to spinning at a rate of two revolutions per second, throughout the acquisition process. The samples were scanned from 2° to 40° in 2θ with a step size of 0.017° and a scan speed of $0.067^{\circ}/\text{sec}$. The data acquisition was controlled and analyzed by X'Pert Data Collector (version 2.2d) and X'Pert Data Viewer (version 1.2c), respectively.

30 The X-ray diffraction pattern for form 2 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is shown in FIG. 4. Unless otherwise specified, the

experimental data for X-ray powder diffraction were collected at room temperature.

HPLC Analysis

5 HPLC analysis is performed as described in Example 1.

Example 3: Synthesis, Purification and Analysis of Crystalline Form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate

10 Approximately 420 mg of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate was heated in a scintillation vial to 70 °C, at which temperature solid (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate completely melted. The molten compound was immediately immersed into liquid nitrogen. The resulting solid was shown to be pure form 3.

15

Differential Scanning Calorimetry (DSC) Analysis

DSC analysis was conducted using a TA Instruments Q2000 DSC equipped with a refrigerated cooling system. For all DSC analyses, 2-5 mg of sample was loaded into
20 T_{zero} aluminum pans with crimped lids. A pinhole was made at the center of the lid to avoid any pressure buildup during heating. Samples were equilibrated at 10 °C and ramped at a heating rate of 2 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data were analyzed with Universal Analysis 2000 software (version 4.5A).

25

The DSC thermogram (FIG. 8) shows that form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate first melts at about 47 °C. The melting is immediately followed by recrystallization and melting. The second melting completes at approximately 60 °C.

Thermogravimetric Analysis (TGA)

Thermal gravimetric analysis was conducted using a TA Instruments Q5000
5 thermogravimetric analyzer. For all TGA analyses, 5-10 mg of sample was loaded onto
a platinum pan and heated at a rate of 2 °C per minute under a purge of dry nitrogen
gas. The data acquisition was controlled by Thermal Advantage software Release
4.9.1. The data was analyzed with Universal Analysis 2000 software (version 4.5A).

10 The TGA thermogram (FIG. 9) shows that form 3 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate does not undergo any weight
loss prior to melting, which indicates that the Form 3 is an anhydrous crystalline solid.

X-ray Powder Diffraction (XRPD) Analysis

15

Powder X-ray diffraction analysis was performed using a PANalytical X'Pert Pro
X-ray diffractometer. The X-ray source was Cu K_{α} radiation ($\lambda = 1.54051 \text{ \AA}$) with output
voltage of 45 kV and current of 40 mA. The instrument adopts a para-focusing Bragg-
Brentano geometry with incident divergence and scattering slits set at $1/16^{\circ}$ and $1/8^{\circ}$
20 respectively. Large Soller slits (0.04 rad) were used for both incident and diffracted
beam to remove axial divergence. A small amount of powder (9-12 mg) was gently
pressed onto the single crystal silicon sample holder to form a smooth surface, and
samples were subjected to spinning at a rate of two revolutions per second, throughout
the acquisition process. The samples were scanned from 2° to 40° in 2θ with a step
25 size of 0.017° and a scan speed of $0.067^{\circ}/\text{sec}$. The data acquisition was controlled and
analyzed by X'Pert Data Collector (version 2.2d) and X'Pert Data Viewer (version 1.2c),
respectively.

The X-ray diffraction pattern for form 3 of the (N,N-Diethylcarbamoyl)methyl
30 methyl (2E)but-2-ene-1,4-dioate is shown in FIG. 7. Unless otherwise specified, the
experimental data for X-ray powder diffraction were collected at room temperature.

HPLC Analysis

HPLC analysis is performed as described in Example 1.

5 **Example 4: Synthesis, Purification and Analysis of Crystalline Form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate**

At a temperature of about 50-70 °C, under a nitrogen atmosphere, a slurry of mono-methyl fumarate (130 g), toluene (800 mL) and *N,N*-diethylchloroacetamide (157
10 g) is added to triethylamine (1.07 g) . The temperature is adjusted to 85-95 °C and maintained there for 4 hours. Then the temperature is then adjusted to 15-25°C and the mixture is subjected to vigorous agitation. After 30 minutes of vigorous agitation in 200 mL of water, the agitation is stopped and the phases are allowed to separate for 30 minutes. The upper organic phase is washed with additional deionized water (75 mL)
15 with vigorous agitation for 30 minutes. The agitation is then stopped and the phases are allowed to separate for 30 minutes. The organic layer is dried over anhydrous sodium sulfate (25 g) for 2 hours. The reaction is filtered and the solution is cooled to 10-20 °C. Heptane (1600 mL), at -5 to -20 °C is added over 5 minutes. The reaction is cooled to -5 °C to - 10 °C for 24 to 48 hours. The resulting product is air dried for 12
20 hours. XRPD analysis confirms product is form 4.

Differential Scanning Calorimetry (DSC) Analysis

DSC analysis was conducted using a TA Instruments Q2000 DSC equipped with
25 a refrigerated cooling system. For all DSC analyses, 2-5 mg of sample was loaded into T_{zero} aluminum pans with crimped lids. A pinhole was made at the center of the lid to avoid any pressure buildup during heating. Samples were equilibrated at 10 °C and ramped to a rate of 2 °C per minute under a purge of dry nitrogen gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data
30 were analyzed with Universal Analysis 2000 software (version 4.5A).

The DSC thermogram (FIG. 11) shows that form 4 of (N,N-

Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate undergoes a solid-solid phase transformation at approximately 38 °C. The resulting solid melts at approximately 58 °C.

5 Thermogravimetric Analysis (TGA)

Thermal gravimetric analysis was conducted using a TA Instruments Q5000 thermogravimetric analyzer. For all TGA analyses, 5-10 mg of sample was loaded onto a platinum pan and heated at a rate of 2 °C per minute under a purge of dry nitrogen
10 gas. The data acquisition was controlled by Thermal Advantage software Release 4.9.1. The data was analyzed with Universal Analysis 2000 software (version 4.5A).

The TGA thermogram (FIG 12) shows that form 4 of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate does not undergo any weight
15 loss prior to melting, which indicates that the form 4 is an anhydrous crystalline solid.

X-ray Powder Diffraction (XRPD) Analysis

Powder X-ray diffraction analysis was performed using a PANalytical X'Pert Pro
20 X-ray diffractometer. The X-ray source was Cu K_{α} radiation ($\lambda = 1.54051 \text{ \AA}$) with output voltage of 45 kV and current of 40 mA. The instrument adopts a para-focusing Bragg-Brentano geometry with incident divergence and scattering slits set at $1/16^{\circ}$ and $1/8^{\circ}$ respectively. Large Soller slits (0.04 rad) were used for both incident and diffracted beam to remove axial divergence. A small amount of powder (9-12 mg) was gently
25 pressed onto the single crystal silicon sample holder to form a smooth surface, and samples were subjected to spinning at a rate of two revolutions per second, throughout the acquisition process. The samples were scanned from 2° to 40° in 2θ with a step size of 0.017° and a scan speed of $0.067^{\circ}/\text{sec}$. The data acquisition was controlled and analyzed by X'Pert Data Collector (version 2.2d) and X'Pert Data Viewer (version 1.2c),
30 respectively.

The X-ray diffraction pattern for form 4 of the (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate is shown in FIG. 10. Unless otherwise specified, the experimental data for X-ray powder diffraction were collected at room temperature.

5 HPLC Analysis

HPLC analysis is performed as described in Example 1.

CLAIMS

What is claimed is:

1. A crystalline form of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate selected from: Crystalline form 1 having a purity of at least 99% by weight as measured by HPLC; Crystalline form 2; Crystalline form 3; or Crystalline form 4.
2. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 1 having a DSC thermogram peak of between about 57 °C and about 59 °C.
3. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 1 exhibiting characteristic scattering angles (2θ) at least at $14.5 \pm 0.2^\circ$, $21.7 \pm 0.2^\circ$, $12.3 \pm 0.2^\circ$, $29.0 \pm 0.2^\circ$, and $27.1 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
4. The crystalline form of claim 3, wherein the crystalline form is Crystalline form 1 exhibiting characteristic scattering angles (2θ) at least at $21.0 \pm 0.2^\circ$, $22.8 \pm 0.2^\circ$, $19.8 \pm 0.2^\circ$, $6.8 \pm 0.2^\circ$, and $20.3 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.
5. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 1 exhibiting characteristic scattering angles (2θ) in an X-ray powder diffraction pattern measured using Cu- K_α radiation shown in FIG. 1.
6. The crystalline form of any of claims 1-5, wherein the crystalline form is Crystalline form 1 having a purity of at least 99.5% by weight as measured by HPLC.
7. The crystalline form of any of claims 1-5, wherein the crystalline form is Crystalline form 1 having a purity of at least 99.9% by weight as measured by HPLC.
8. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 2 having a DSC thermogram peak of between about 49 °C and about 51 °C.
9. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 2 exhibiting characteristic scattering angles (2θ) at least at $8.4 \pm 0.2^\circ$, $4.2 \pm 0.2^\circ$, $16.9 \pm 0.2^\circ$, $18.3 \pm 0.2^\circ$, $20.0 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu- K_α radiation.

10. The crystalline form of claim 9, wherein the crystalline form is Crystalline form 2 exhibiting characteristic scattering angles (2θ) at least at $26.8 \pm 0.2^\circ$, $23.5 \pm 0.2^\circ$, $29.8 \pm 0.2^\circ$, $20.7 \pm 0.2^\circ$ and $24.2 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

5 11. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 2 exhibiting characteristic scattering angles (2θ) in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation shown in FIG. 4.

12. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 3 having a DSC thermogram peak of between about 46°C and about 48°C .

10 13. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 3 which exhibits characteristic scattering angles (2θ) at least at $20.6 \pm 0.2^\circ$, $9.5 \pm 0.2^\circ$, $11.1 \pm 0.2^\circ$, $15.8 \pm 0.2^\circ$, and $18.6 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

14. The crystalline form of claim 13, wherein the crystalline form is Crystalline form 3 which exhibits characteristic scattering angles (2θ) at least at $20.8 \pm 0.1^\circ$, $29.2 \pm 0.1^\circ$, $19.1 \pm 0.1^\circ$, $22.2 \pm 0.1^\circ$, and $24.3 \pm 0.1^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

15 15. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 3 which exhibits characteristic scattering angles (2θ) in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation shown in FIG. 7.

16. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 4 having a DSC thermogram peak of between about 37°C and about 39°C .

17. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 4 which exhibits characteristic scattering angles (2θ) at least at $20.4 \pm 0.2^\circ$, $8.2 \pm 0.2^\circ$, $33.2 \pm 0.2^\circ$, $26.3 \pm 0.2^\circ$, and $20.8 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

18. The crystalline form of claim 17, wherein the crystalline form is Crystalline form 4 which exhibits characteristic scattering angles (2θ) at least at $8.3 \pm 0.2^\circ$, $26.2 \pm 0.2^\circ$, $13.2 \pm 0.2^\circ$, $16.4 \pm 0.2^\circ$, and $21.8 \pm 0.2^\circ$ in an X-ray powder diffraction pattern measured using Cu-K $_{\alpha}$ radiation.

19. The crystalline form of claim 1, wherein the crystalline form is Crystalline form 4 which exhibits characteristic scattering angles (2θ) in an X-ray powder diffraction pattern measured using Cu-K α radiation shown in FIG. 10.

20. A pharmaceutical composition comprising a crystalline form of any of
5 claims 1-19 and a pharmaceutically acceptable vehicle.

21. A dosage form comprising a therapeutically effective amount of a crystalline form of any of claims 1-19 and a pharmaceutically acceptable vehicle.

22. The dosage form of claim 21, wherein the dosage form is an oral dosage form.

10 23. A crystalline form of any of claims 1-19, a pharmaceutical composition according to claim 20, or a dosage form according to claims 21 or 22, for use in the treatment of a disease in a patient in need thereof.

24. A crystalline form of claim 23, wherein the disease is selected from multiple sclerosis and psoriasis.

15 25. A crystalline form of claim 23, wherein the disease is selected from acute dermatitis, acute disseminated encephalomyelitis, Addison's disease, adrenal leukodystrophy, AGE-induced genome damage, Alexanders Disease, alopecia areata (totalis and universalis), Alper's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, angina pectoris, ankylosing spondylitis, antiphospholipid antibody syndrome,
20 arthritis, asthma, autoimmune carditis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, balo concentric sclerosis, Behcet's disease, bullous pemphigoid, Canavan disease, cardiac insufficiency including left ventricular insufficiency, celiac disease, central nervous system vasculitis, Chagas disease, Charcott-Marie-Tooth Disease, childhood ataxia with central nervous system
25 hypomyelination, chronic dermatitis, chronic idiopathic peripheral neuropathy, chronic obstructive pulmonary disease, contact dermatitis, Crohn's disease, cutaneous Crohn's disease, cutaneous lupus, cutaneous sarcoidosis, dermatomyositis, diabetes mellitus type I, diabetic retinopathy, eczema, endometriosis, globoid cell leukodystrophy (Krabbe Disease), Goodpasture's syndrome, graft versus host disease, granulomas
30 including annulaire, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hepatitis C viral infection, herpes simplex viral infection, hidradenitis suppurativa,

human immunodeficiency viral infection, Huntington's disease, idiopathic thrombocytopenic purpura, IgA neuropathy, inflammatory bowel disease, interstitial cystitis, irritable bowel disorder, ischemia, Kawasaki disease, lichen planus, lupus, lupus erythematosus, macular degeneration, mitochondrial encephalomyopathy, mixed
5 connective tissue disease, monomelic amyotrophy, morphea, multiple sclerosis, myasthenia gravis, myocardial infarction, narcolepsy, neurodegeneration with brain iron accumulation, neuromyelitis optica, neuromyotonia, neurosarcoidosis, NF- κ B mediated diseases, optic neuritis, parenoplastic syndromes, Parkinson's disease, Pelizaeus-Merzbacher disease, pemphigus, pernicious anaemia, polymyositis, primary biliary
10 cirrhosis, primary lateral sclerosis, progressive supranuclear palsy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, reperfusion injury, retinopathia pigmentosa, rheumatica, sarcoidosis, Schilders Disease, schizophrena, scleroderma, Sjogren's syndrome, stiff person syndrome, subacute necrotizing myelopathy, susac syndrome, temporal arteritis, transplantation rejection, transverse myelitis, a tumor, ulcerative
15 colitis, vasculitis, vitiligo, Wegener's granulomatosis and Zellweger's syndrome.

1/12




FIG. 1

2/12




FIG. 2

3/12




FIG. 3

4/12




FIG. 4

5/12




FIG. 5

6/12




FIG. 6

7/12




FIG. 7

8/12




FIG. 8

9/12




FIG. 9

10/12




FIG. 10

11/12




FIG. 11

12/12




FIG. 12

INTERNATIONAL SEARCH REPORT

International application No PCT/US2014/054319

A. CLASSIFICATION OF SUBJECT MATTER		
INV.	A61K31/225 A61P25/28 C07C235/06 A61P31/22 A61P31/18	
	A61P31/12 A61P29/00 A61P11/06 A61P3/10 A61P17/06	
ADD.		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C07C C07B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, WPI Data, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2010/048651 A1 (GANGAKHEDKAR ARCHANA [US] ET AL) 25 February 2010 (2010-02-25) paragraphs [0043], [0143] paragraph [0332] - paragraph [0370]	1-25
X,P	WO 2014/071371 A1 (XENOPORT INC [US]) 8 May 2014 (2014-05-08) claims; table 1	1-25
X,P	WO 2014/031894 A1 (XENOPORT INC [US]; WUSTROW DAVID J [US]; VIRSIK PETER A [US]) 27 February 2014 (2014-02-27) example 14	1-25
X,P	WO 2014/031897 A1 (XENOPORT INC [US]; WUSTROW DAVID J [US]; VIRSIK PETER A [US]) 27 February 2014 (2014-02-27) example 2	1-25
	----- -/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents :		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
18 November 2014	01/12/2014	
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Österle, Carmen	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2014/054319

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>KAMLESH D. SAWANT ET AL: "Necessity of Establishing Chemical Integrity of Polymorphs of Drug Substance Using a Combination of NMR, HPLC, Elemental Analysis, and Solid-State Characterization Techniques: Case Studies", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 17, no. 3, 15 March 2013 (2013-03-15), pages 519-532, XP055060451, ISSN: 1083-6160, DOI: 10.1021/op300229k page 519, right-hand column - page 520</p> <p style="text-align: center;">-----</p>	1-25
X	<p>CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2_5 Chapter 3.1</p> <p style="text-align: center;">-----</p>	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2014/054319

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2010048651 A1	25-02-2010	AU 2009282888 A1	25-02-2010
		CA 2730478 A1	25-02-2010
		CA 2806444 A1	25-02-2010
		CN 102123763 A	13-07-2011
		DK 2334378 T3	07-07-2014
		EP 2334378 A2	22-06-2011
		EP 2650279 A2	16-10-2013
		ES 2477884 T3	18-07-2014
		HK 1158563 A1	22-08-2014
		JP 2012500285 A	05-01-2012
		NZ 590746 A	26-10-2012
		NZ 602496 A	27-09-2013
		NZ 608196 A	26-09-2014
		PT 2334378 E	16-07-2014
		RU 2011110435 A	27-09-2012
		SI 2334378 T1	31-07-2014
		US 2010048651 A1	25-02-2010
		US 2012095003 A1	19-04-2012
		US 2012157523 A1	21-06-2012
		US 2014329818 A1	06-11-2014
		WO 2010022177 A2	25-02-2010

WO 2014071371 A1	08-05-2014	US 2014179778 A1	26-06-2014
		WO 2014071371 A1	08-05-2014

WO 2014031894 A1	27-02-2014	US 2014056973 A1	27-02-2014
		US 2014056978 A1	27-02-2014
		US 2014065211 A1	06-03-2014
		WO 2014031892 A1	27-02-2014
		WO 2014031894 A1	27-02-2014
		WO 2014031897 A1	27-02-2014

WO 2014031897 A1	27-02-2014	US 2014056973 A1	27-02-2014
		US 2014056978 A1	27-02-2014
		US 2014065211 A1	06-03-2014
		WO 2014031892 A1	27-02-2014
		WO 2014031894 A1	27-02-2014
		WO 2014031897 A1	27-02-2014
